Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Provencio

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Cancer Chemotherapy and Pharmacology|October 12, 2012
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancerM Provencio, C Camps, M Cobo, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 27, 2015
SEOM clinical guidelines for the treatment of Hodgkin's lymphomaA Rueda Domínguez, J Alfaro Lizaso, L de la Cruz Merino, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 21, 2015
SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphomaM Provencio Pulla, J Alfaro Lizaso, L de la Cruz Merino, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 23, 2001
Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 casesB Cutuli, C Borel, F Dhermain, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 30, 2017
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 databaseJ Remon, D Isla, P Garrido, et al.
ESMO Open|October 4, 2021
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitorR Serna-Blasco, E Sánchez-Herrero, S Sanz-Moreno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2005
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trialC Camps, B Massuti, A Jiménez, et al.
Lung Cancer (Amsterdam, Netherlands)|July 15, 2010
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbineN Viñolas, M Provencio, N Reguart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trialV Alberola, C Camps, M Provencio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2017
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trialA Abad, E Martínez-Balibrea, J M Viéitez, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Cancer Chemotherapy and Pharmacology|October 12, 2012
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancerM Provencio, C Camps, M Cobo, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 27, 2015
SEOM clinical guidelines for the treatment of Hodgkin's lymphomaA Rueda Domínguez, J Alfaro Lizaso, L de la Cruz Merino, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 21, 2015
SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphomaM Provencio Pulla, J Alfaro Lizaso, L de la Cruz Merino, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 23, 2001
Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 casesB Cutuli, C Borel, F Dhermain, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 30, 2017
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 databaseJ Remon, D Isla, P Garrido, et al.
ESMO Open|October 4, 2021
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitorR Serna-Blasco, E Sánchez-Herrero, S Sanz-Moreno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2005
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trialC Camps, B Massuti, A Jiménez, et al.
Lung Cancer (Amsterdam, Netherlands)|July 15, 2010
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbineN Viñolas, M Provencio, N Reguart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trialV Alberola, C Camps, M Provencio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2017
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trialA Abad, E Martínez-Balibrea, J M Viéitez, et al.
Pageof 11